| 中文名称 |
Ocrelizumab (anti-CD20) |
| 中文别名 |
OCRELIZUMAB ( 奥瑞组单抗 );奥瑞组单抗;奥克立珠单抗 |
| 英文名称 |
Ocrelizumab (anti-CD20) |
| 英文别名 |
Ocrelizumab;Research Grade Ocrelizumab(DHC90702);Roxadustat(FG-4592);ASP1517;BCP02523;2-(4-hydroxy-1-Methyl-7-phenoxyisoquinoline-3-carboxaMido)acetic acid;AMY16514;SMR004701207;N-[(4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine;FG-4592,ASP1517;Q27088611;FG-4592;FG-4592 (ASP1517);s1007;FG 4592;BCPP000230;Glycine, N-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]-;UNII-X3O30D9YMX;EX-A390;HY-13426;(((4-Hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl)amino)acetic acid;CS-1094;CHEBI:132774;Evrenzo;2-[[4-hydroxy-1-methyl-7-(phenoxy)isoquinoline-3-carbonyl]amino]acetic acid;NCGC00346527-01;MFCD20040519;ASP 1517;AS-17052;J-522733;808118-40-3;Roxadustat [USAN:INN];NCGC00346527-07;AC-31003;GLYCINE, N-((4-HYDROXY-1-METHYL-7-PHENOXY-3-ISOQUINOLINYL)CARBONYL)-;Roxadustat (FG-4592);X3O30D9YMX;AZD 9941;HMS3654M03;AKOS026674331;SB16615;CHEMBL2338329;ROXADUSTAT [JAN];MLS006010023;N-[(4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]glycine;Roxadustat;(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)glycine;8HO;GTPL8454;2-[(1-methyl-4-oxidanyl-7-phenoxy-isoquinolin-3-yl)carbonylamino]ethanoic acid;D10593;637334-45-3;ROXADUSTAT [USAN];YOZBGTLTNGAVFU-UHFFFAOYSA-N;Roxadustat (JAN/USAN/INN);ROXADUSTAT [WHO-DD];n-((4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl)glycine;DB04847;BCP9000684;Fg-4592[roxadustat];D03YKE;SCHEMBL523705;DTXSID60230644;BDBM50431015;N-[(4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]-glycine, Roxadustat;Evrenzo (TN);ROXADUSTAT [INN];roxadustatum;CCG-268052;SW219900-1;2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid;ASP-1517;FG4592 |
| CAS No. |
637334-45-3 |
| 分子式 |
C19H16N2O5 |
| 分子量 |
352.34 |
| 纯度 |
无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
